Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03352245
Other study ID # 2000022225
Secondary ID 1P50CA196530-01
Status Completed
Phase N/A
First received
Last updated
Start date November 26, 2018
Est. completion date May 24, 2020

Study information

Verified date February 2024
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators will evaluate the feasibility of implementing a low-intensity, patient-centered activity regimen (PCAR) that prioritizes education and communication over a 12-week period in advanced stage lung cancer patients. The primary outcomes will include number of patients increasing their overall step count over the study period and adherence to step count recommendations. Secondary outcomes will include quality of life (QoL), dyspnea, and depression scores before and after the intervention as well as a patient feedback questionnaire (to guide further interventions). The goals are to increase overall step count and obtain adherence of >50% of participants. The investigators will also assess whether the physical activity regimen influences markers of inflammation and glucose control and novel markers of cancer.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date May 24, 2020
Est. primary completion date May 24, 2020
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - Pathologic evidence of advanced non-small cell stage lung cancer (NSCLC) - Approval of the treating clinician - Adult patients (age >21 years) willing to wear a FitBit® device (FitBit, Inc., San Francisco, CA) - Access to a smartphone, agree to receive twice/daily text messages for 12 weeks (including any costs), and willingness to download the FitBit application to their smartphone. - Low activity level as judged by a brief physical activity questionnaire (i.e., <150 minutes/week of moderate-intensity exercise, <75 minutes/week of vigorous aerobic exercise, or an equivalent combination). Exclusion Criteria: - Memory impairment (as judged by the treating clinician) - Communication impairment (as judged by the treating clinician) - Treating clinician's request not to alter physical activity - Physical inability to safely walk (as judged by the treating clinician)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Prescribed Activity
Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)

Locations

Country Name City State
United States Yale University New Haven Connecticut

Sponsors (4)

Lead Sponsor Collaborator
Yale University Medical University of South Carolina, National Cancer Institute (NCI), VA Connecticut Healthcare System

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Step Count Participants will wear a Fitbit wrist band that will record step count. baseline to 12 weeks
Primary Number of Weeks Participants Adhered to Step Count Recommendations Exercise Adherence will be defined as (the number of weeks a subject follows the activity prescription)/(the number of "usable" weeks). A week is considered "usable" if 5/7 days of step counts are available, and days with <200 steps/day are considered not usable. baseline to 12 weeks.
Secondary Dyspnea Assessed via self-report using the Modified Medical Research Council. Dyspnea Scale, a single-item scale scored 0-4; higher score indicates worse dyspnea. change from pre- to post-intervention (week 12)
Secondary Depression Assessed via self-report using the Patient Health Questionnaire, Depression Module (PHQ-9). a 9-item questionnaire that assesses depressive symptoms over the preceding two weeks. Each item is scored 0-3 (0 = "Not at all"; 1 = "Several days"; 2 = "More than half of days"; 3 = "Nearly every day"). A total score is calculated by taking the sum of questions 1-9, and a higher score indicates worse depression. change from pre- to post-intervention (week 12)
Secondary Change in Quality of Life: Global Health Status Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales:
Global health status/Quality of Life (QoL) scale, range 0-100, higher score = better quality of life.
change from pre- to post-intervention (week 12)
Secondary Change in Quality of Life: Physical Functioning Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measure physical functioning.
The range of score is 0-100; higher score = better functioning.
change from pre- to post-intervention (week 12)
Secondary Change in Quality of Life: Role Functioning Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measures role functioning.
The range of score is 0-100; higher score = better functioning.
change from pre- to post-intervention (week 12)
Secondary Change in Quality of Life: Emotional Functioning Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measures emotional functioning.
The range of score is 0-100; higher score = better functioning.
change from pre- to post-intervention (week 12)
Secondary Change in Quality of Life: Fatigue Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the symptom scale measures fatigue.
The range of score is 0-100; higher score = better functioning.
change from pre- to post-intervention (week 12)
Secondary Change in Quality of Life: Cognitive Functioning Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measures cognitive functioning.
The range of score is 0-100; higher score = better functioning.
change from pre- to post-intervention (week 12)
Secondary Change in Quality of Life: Nausea/Vomiting Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the symptom scale measures nausea and vomiting The range of score is 0-100; higher score = better functioning. change from pre- to post-intervention (week 12)
Secondary Change in Quality of Life: Pain Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the symptom scale measures pain.
The range of score is 0-100; higher score = better functioning.
change from pre- to post-intervention (week 12)
Secondary Change in Quality of Life: Social Functioning Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the 5 functional scales measures social functioning.
The range of score is 0-100; higher score = better functioning.
change from pre- to post-intervention (week 12)
Secondary Change in Quality of Life: Dyspnea Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure dyspnea.
The range of score is 0-100; higher score = higher symptoms burden.
change from pre- to post-intervention (week 12)
Secondary Change in Quality of Life: Insomnia Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure insomnia.
The range of score is 0-100; higher score = better functioning.
change from pre- to post-intervention (week 12)
Secondary Change in Quality of Life: Appetite Loss Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure appetite loss The range of score is 0-100; higher score = higher symptoms burden. change from pre- to post-intervention (week 12)
Secondary Change in Quality of Life: Constipation Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure constipation.
The range of score is 0-100; higher score = higher symptoms burden.
change from pre- to post-intervention (week 12)
Secondary Change in Quality of Life: Diarrhea Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure diarrhea.
The range of score is 0-100; higher score = higher symptoms burden.
change from pre- to post-intervention (week 12)
Secondary Change in Quality of Life: Financial Difficulties Assessed via self-report using the European Organization for the Research and Treatment of Cancer, Quality of Life Questionnaire (QLQ-C30, Version 3). The scale measures quality of life in 30 questions with 15 subscales. One of the scales measure financial difficulties.
The range of score is 0-100; higher score = higher symptoms burden.
change from pre- to post-intervention (week 12)
Secondary Moderate Aerobic Exercise The investigators will use the Physical Activity Questionnaire that measures this outcome in minutes. baseline to 12 weeks
Secondary Vigorous Aerobic Exercise The investigators will use the Physical Activity Questionnaire that measures this outcome in minutes. baseline to 12 weeks
Secondary Change in C-reactive Protein (CRP) The investigators will obtain serum CRP, a marker of inflammation. change from pre- to post-intervention (week 12)
Secondary Change in Leptin Level The investigators will obtain serum leptin, a marker of glucose control. . change from pre- to post-intervention (week 12)
Secondary Change in Insulin Level The investigators will obtain serum insulin level, a measure of glucose control. change from pre- to post-intervention (week 12)
Secondary Programmed Death - Ligand The investigators will collect soluble PD- L1, a novel cancer marker. change from pre- to post-intervention (week 12)
Secondary Programmed Cell Death (PD-1) The investigators will collect soluble PD- 1, a novel cancer marker. change from pre- to post-intervention (week 12)
See also
  Status Clinical Trial Phase
Recruiting NCT05890872 - Aliya™ Pulsed Electric Fields (PEF) for Advanced Cancer N/A
Recruiting NCT05974475 - MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell Lung Cancer
Recruiting NCT06079970 - Confocal Laser Endomicroscopy VERification N/A
Recruiting NCT04973293 - Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer N/A
Recruiting NCT04778826 - Immune Response Following Lobectomy Along With or Without Bilateral Transcervical Mediastinal Lymphadenectomy N/A
Suspended NCT04036721 - Coorticosteroid Regimen in Patients With Anti-PD-1/PD-L1 Induced Pneumonitis Phase 4
Completed NCT03834116 - Resistance Inspiratory Muscle Training for Patients With Thoracic Malignancies N/A
Completed NCT03824977 - Prognostic Value of the 6-minute Stepper Test in Non-small Cell Lung Cancer Surgery
Terminated NCT02985203 - Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer Phase 2
Recruiting NCT06440616 - Benefit of Spectral Information in Patients Suspected for Lung Cancer N/A
Active, not recruiting NCT05241873 - (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations Phase 1/Phase 2
Completed NCT05404022 - Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years N/A
Not yet recruiting NCT05414188 - Beneficial Effect of Pulmonary Rehabilitation in Lung Cancer Patients Receiving Radiation Therapy N/A
Recruiting NCT03525782 - Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC Phase 1/Phase 2
Completed NCT04059887 - Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY] Phase 4
Terminated NCT05013554 - Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors Phase 1